Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2017

Segments and Geographic Information [Abstract]

Schedule of revenue by geographic location

We generated third-party revenue in the following geographic locations⁽¹⁾ during each of the periods presented below (in millions):

	Year Ended				Six Months Ended		Year Ended
	December 31, 2017		December 31, 2016		December 31, 2015		June 27, 2015
Ireland	$	30.4	$	89.1	$	11.4	$	7.2
U.S.	3,272.3		3,353.0		1,686.2		3,303.2
Europe	1,313.2		1,493.0		758.2		576.4
All other countries(2)	330.3		345.5		176.4		340.3
	$	4,946.2	$	5,280.6	$	2,632.2	$	4,227.1

⁽¹⁾The net sales by geography is derived from the location of the entity that sells to a third party.

⁽²⁾Includes revenue generated primarily in Israel, Mexico, Australia, and Canada.

Schedule of property and equipment by geographic location

The net book value of Property, plant and equipment, net by location was as follows (in millions):

	December 31, 2017		December 31, 2016		December 31, 2015
Ireland	$	4.6	$	2.7	$	1.3
U.S.	538.3		556.6		555.0
Europe	155.6		144.6		157.2
Israel	81.5		114.3		115.7
All other countries	53.1		51.9		57.0
	$	833.1	$	870.1	$	886.2

Schedules of Concentration of Risk, by Risk Factor

Sales to Walmart as a percentage of Consolidated Net sales (reported primarily in our CHCA segment) were as follows:

Year Ended				Six Months Ended		Year Ended
December 31, 2017		December 31, 2016		December 31, 2015		June 27, 2015
13.0	%	13.0	%	13.0	%	16.0	%

Schedule of segment reporting information, by segment

Below is a summary of our results by reporting segment (in millions):

	CHCA			CHCI(1)			RX			Specialty Sciences			Other				Unallocated			Total
Year Ended December 31, 2017
Net sales	$	2,429.9		$	1,491.0		$	969.7		$	—		$	55.6			$	—		$	4,946.2
Operating income (loss)	$	445.0		$	12.5		$	307.6		$	—		$	8.7			$	(175.6	)	$	598.2
Operating income (loss) %	18.3		%	0.8		%	31.7		%	—		%	15.6		%		—		%	12.1		%
Total assets	$	3,786.8		$	5,029.0		$	2,813.0		$	—		$	—			$	—		$	11,628.8
Capital expenditures	$	39.5		$	27.5		$	21.6		$	—		$	—			$	—		$	88.6
Property, plant and equipment, net	$	512.7		$	180.9		$	139.5		$	—		$	—			$	—		$	833.1
Depreciation/amortization	$	115.2		$	223.7		$	100.1		$	—		$	5.8			$	—		$	444.8
Change in financial assets	$	—		$	—		$	—		$	24.9		$	—			$	—		$	24.9
Year Ended December 31, 2016
Net sales	$	2,507.1		$	1,652.2		$	1,042.8		$	—		$	78.5			$	—		$	5,280.6
Operating income (loss)	$	399.8		$	(2,087.4	)	$	(0.2	)	$	(201.2	)	$	6.1			$	(116.8	)	$	(1,999.7	)
Operating income (loss) %	15.9		%	(126.3		)%	—		%	—		%	7.8		%		—		%	(37.9		)%
Total assets	$	3,351.3		$	4,795.2		$	2,646.4		$	2,775.8		$	301.4			$	—		$	13,870.1
Capital expenditures	$	59.1		$	23.7		$	20.4		$	—		$	3.0			$	—		$	106.2
Property, plant and equip, net	$	528.3		$	167.2		$	129.7		$	0.4		$	44.5			$	—		$	870.1
Depreciation/amortization	$	119.1		$	210.0		$	120.1		$	—		$	7.8			$	—		$	457.0
Change in financial assets	$	—		$	—		$	—		$	2,608.2		$	—			$	—		$	2,608.2
Six Months Ended December 31, 2015
Net sales	$	1,251.5		$	833.0		$	502.6		$	—		$	45.1			$	—		$	2,632.2
Operating income (loss)	$	209.2		$	(148.5	)	$	181.9		$	(6.5	)	$	(19.5	)		$	(149.0	)	$	67.6
Operating income (loss) %	16.7		%	(17.8		)%	36.2		%	—		%	(43.3		)%		—		%	2.6		%
Total assets	$	3,384.8		$	7,083.5		$	2,738.0		$	5,930.2		$	213.1			$	—		$	19,349.6
Capital expenditures	$	38.0		$	26.3		$	12.1		$	—		$	1.4			$	—		$	77.8
Property, plant and equip, net	$	540.9		$	179.5		$	118.5		$	—		$	47.3		—	$	—		$	886.2
Depreciation/amortization	$	60.9		$	81.9		$	34.3		$	—		$	5.3			$	—		$	182.4
Change in financial assets	$	—		$	—		$	—		$	(57.3	)	$	—			$	—		$	(57.3	)
Year Ended June 27, 2015
Net sales	$	2,478.8		$	704.6		$	936.0		$	—		$	107.7			$	—		$	4,227.1
Operating income (loss)	$	381.9		$	38.2		$	364.7		$	(17.6	)	$	26.8			$	(121.5	)	$	672.5
Operating income %	15.4		%	5.4		%	39.0		%	—		%	24.9		%		—		%	15.9		%
Total assets	$	3,763.8		$	7,163.0		$	2,373.4		$	6,040.7		$	251.0			$	—		$	19,591.9
Capital expenditures	$	76.8		$	13.1		$	41.0		$	0.5		$	5.6			$	—		$	137.0
Property, plant and equip, net	$	556.8		$	176.8		$	113.0		$	—		$	85.8			$	—		$	932.4
Depreciation/amortization	$	108.4		$	72.5		$	65.7		$	1.5		$	10.6			$	—		$	258.7
Change in financial assets	$	—		$	—		$	—		$	(78.5	)	$	—			$	—		$	(78.5	)

⁽¹⁾     CHCI includes Omega activity subsequent to March 30, 2015.

Schedule of sales by major product category

The following is a summary of our revenue by category (in millions):

	Year Ended				Six Months Ended		Year Ended
	December 31, 2017		December 31, 2016		December 31, 2015		June 27, 2015
CHCA
Cough/Cold/Allergy/Sinus(1)	$	483.7	$	454.6	$	234.6	$	455.6
Analgesics(1)	349.8		343.5		173.1		375.7
Gastrointestinal(1)	340.0		335.4		195.8		384.0
Infant nutritionals	413.9		427.0		200.2		383.8
Smoking cessation	297.2		308.5		147.5		284.5
Vitamins, minerals and dietary supplements(1)	45.4		160.4		105.8		183.5
Animal health	141.3		143.7		62.3		157.0
Other CHCA(1),(2)	358.6		334.0		132.2		254.7
Total CHCA	2,429.9		2,507.1		1,251.5		2,478.8
CHCI
Branded OTC	1,174.0		1,349.2		665.9		368.4
Other CHCI(3)	317.0		303.0		167.1		336.2
Total CHCI	1,491.0		1,652.2		833.0		704.6
Generic prescription drugs	969.7		1,042.8		502.6		936.0
Active pharmaceutical ingredients	55.6		78.5		45.1		107.7
Total revenue	$	4,946.2	$	5,280.6	$	2,632.2	$	4,227.1

⁽¹⁾Includes net sales from our OTC contract manufacturing business.

⁽²⁾  Consists primarily of feminine hygiene, diabetes care, dermatological care, branded OTC, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCA segment.

⁽³⁾  Consists primarily of liquids licensed products, cough/cold/allergy, analgesics, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCI segment.